UNSPSC 51263118: Nicainoprol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C21H27N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UA960P80H, chemically known as 1,2,3,4-tetrahydro-8-(2-hydroxy-3-(isopropylamino)propoxy)-1-(3-pyridylcarbonyl)quinoline but generally known as nicainoprol, which bears US NIH Compound Identifier 71147. European Medicines Agency schedules Nicainoprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09221MIG.

UNSPSC 51263118 Nicainoprol is a Commodity code that covers pharmaceutical products procured by state and local health agencies, though recent activity under this specific code shows limited alignment with traditional pharmaceutical procurement. State and local governments soliciting under this code span county health departments, state health commissions, and community health systems focused on emergency response and pharmacy benefit management. The scope of work includes the purchase of pharmaceutical products and related health interventions, with recent opportunities demonstrating procurement of naloxone and drug deactivation systems by public health authorities and exploratory contracting for direct-to-manufacturer prescription fulfillment models within state health benefit programs.

Recent activity centers on Florida and Texas. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the county community health building and an initial two-year term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 as exploratory market intelligence for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking vendor capabilities for direct contracting with self-insured health plans and state agencies outside traditional pharmacy benefit managers and wholesalers. Both opportunities reflect state and local investment in pharmaceutical supply chain innovation and emergency health response infrastructure.